ANAPTYSBIO, INC
No SEC Form 4 filings for $ANAB in the last 30 days.
ANAPTYSBIO, INC (ANAB) filed a Rule 144 notice regarding the proposed sale of 15,467 shares of common stock stemming from a stock option exercise dated May 21, 2026. The filing also disclosed two previous dispositions by Dennis Mulroy totaling 20,000 shares in mid-May 2026. This is a routine compliance filing, categorized as neutral in its impact and sentiment.
AnaptysBio, Inc. has successfully spun off its biopharma operations into First Tracks Biotherapeutics, Inc., transforming itself into a royalty management entity. The company will now focus on financial collaborations for Jemperli and imsidolimab, operating virtually with minimal expenses and a strong cash position. This restructuring has led to a significant return for ANAB shareholders, with First Tracks Bio independently trading under the symbol TRAX on Nasdaq.
Skandinaviska Enskilda Banken AB publ significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 333.1% in Q3, now holding 145,191 shares valued at approximately $4.45 million. Other institutional investors like Assenagon Asset Management S.A. also dramatically boosted their holdings, indicating strong institutional accumulation. AnaptysBio's board has authorized a $100 million share buyback, and analysts maintain a "Moderate Buy" rating with an average target price of $66.89 against a current trading price near $54.
